skin

Argireline

FDA: not-FDA-approved

Argireline is a topical peptide that mimics the N-terminal end of SNAP-25 to inhibit neurotransmitter release at the neuromuscular junction, reducing facial tension and minimizing dynamic wrinkles -- functioning as a milder, non-invasive alternative to Botox. Mimics the N-terminal end of SNAP-25, a protein involved in muscle contraction. Inhibits the release of neurotransmitters at the neuromuscular junction, reducing facial muscle tension. Minimizes the appearance of dynamic wrinkles (expression lines). Similar mechanism to botulinum toxin but milder and non-invasive. - Anti-wrinkle and skin smoothing - Dynamic wrinkle reduction (forehead, crow's feet) - Non-invasive Botox alternative - Cosmetic skin rejuvenation - Standard:

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight
Half-life
CAS number
Route
02

Sourcing

Current prices

Updated today

200mg

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
DURING CYCLE
  • None required (topical only)
POST-CYCLE
  • None required
Safety & Regulatory Status
FDA STATUS not-FDA-approved

Regulatory status for Argireline may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.